BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease
Stockholm, Sweden, May 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer’s Clinical Trials Consortium (ACTC) and BioArctic’s partner Eisai have announced the selection of BAN2401 to be evaluated in an upcoming clinical study targeting secondary prevention of Alzheimer’s disease (the A45 study). This study will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health (NIH), and Eisai. The ACTC, which is an NIA-funded clinical trial network with 35